Ginkgo Bioworks
DNA
11.47
-0.94
-7.57%
Ginkgo Bioworks
US · DNA
#3438 by market cap
11.47
-0.94
-7.57%
Live - 5344 symbols - heartbeat 286s ago
· 2026-10-08 09:20
Pre-market
10.92
-4.80%
After-hours
11.31
-1.40%
Overnight
11.46
-0.09%
- Market cap
- 772.39M
- P/E (TTM)i
- -2.29
- P/Bi
- 1.84
- EPSi
- -5.64
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on DNA?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/5/8
-
Company notice
Sonim Technologies | 3: Initial statement of beneficial ownership of securities-10% Owner DNA Holdings Venture Inc.SEC · 2026/2/21
-
Rating change
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $12Market Newswire · 2026/1/8
-
Company notice
DNA Chip Research: Change report (special case target stocks, etc.)EDINET · 2025/6/6
-
TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9Market Newswire · 2026/8/7
-
Company notice
DNA Chip Research: Interim report.EDINET · 2025/6/3
-
Company notice
DNA X | 8-K: DNA X, Inc. Reports First Quarter 2026 Financial ResultsSEC · 2026/5/21
-
Rating change
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $5Market Newswire · 2026/3/12
-
Rating change
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell RatingMarket Newswire · 2026/8/14
-
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5Market Newswire · 2026/9/4
-
Press Release: DNA X, Inc. Reports Second Quarter 2026 Financial ResultsDow Jones · 2026/8/20
-
Rating change
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Cuts Target Price to $14Market Newswire · 2025/11/7
-
Rating change
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Raises Target Price to $9Market Newswire · 2025/8/25
-
Rating change
William Blair Initiates Ginkgo Bioworks(DNA.US) With Sell RatingMarket Newswire · 2026/8/6
-
Rating change
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2025/10/14
-
Company notice
8-K: Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. HaywardSEC · 2025/6/18
-
Kala Bio and Virotek Sign Letter of Intent With U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing ProductsGlobeNewswire · 2026/9/24
-
Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5.Market Newswire · 2026/7/31
-
Rating change
TR | OpenAI - 4o Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Raises Target Price to $12Market Newswire · 2025/8/12
-
Rating change
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)TipRanks · 2026/5/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 09:20:28 · For reference only, not investment advice and not tailored to your situation.